UK-based pharmaceutical company KalVista has dosed the first patient in its Phase I first-in-human clinical trial of KVD818 to treat hereditary angioedema (HAE).
KalVista-developed KVD818 is a new potent product that selectively inhibits plasma kallikrein, thereby preventing attacks of edema in patients suffering from HAE.
Plasma kallikrein is a serine protease and a key component of the body’s inflammatory response, which is responsible for the dilation of blood vessels and increased vascular permeability, edema, and inflammation.
Conducted in the UK, the clinical trial has been designed to assess the safety, drug exposure and bioactivity (plasma kallikrein inhibition) of KVD818 following its oral administration to patients.
The result of the trial is expected to be announced early next year.
KalVista CEO Andrew Crockett said: “The successful dosing of the first subject in this first-in-human clinical trial is an important milestone for the KVD818 development programme and a first step in our goal of developing a best in class oral plasma kallikrein inhibitor for HAE.
“We believe that an oral drug for the treatment of HAE will be an important advancement for patients who suffer from this condition.”
HAE is a rarely occurring, malignant genetic condition triggering symptoms such as sudden and prolonged attacks of edema, which often occur in the hands, feet, face, gastrointestinal tract, and airway.
The attacks can result in severe swelling and pain, airway blockage, and nausea. The treatment of HAE includes addressing both prophylaxis and management of acute attacks.
KalVista is planning to conduct the Phase II trial of KVD818 for HAE depending on the Phase I study results.